Y mabs Therapeutics inc (YMAB) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access YMAB Annual Balance Sheets →
Examining balance sheet movements between Y mabs Therapeutics inc and Jun 30 2024 reveals how Jun 30 2025 adjusts its asset composition and liability profile.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2025)
(Mar 31 2025) (Dec 31 2024) (Sep 30 2024) (Jun 30 2024)
Assets
Cash & cash equivalent62.29
Cash & Short-term Investments62.00
Accounts receivable15.74
Insurance Settlements Receivable, Current0.00
Inventories9.72
Other Current Assets4.04
Total Current Assets91.79
Equipment/Property/Plant Net0.27
Intangible Assets2.18
Other Assets, Noncurrent21.00
Operating Lease Right Of Use Asset3.11
Total Assets117.21
Liabilities
Accounts Payable, Current AC7.57
Accrued Liabilities, Current AC14.89
Other Liabilities, Current0.49
Total Current Liabilities22.95
Total Long-term Debt0.00
Other liabilities, Noncurrent6.77
AccruedMilestoneAndRoyaltyPaymentsNoncurrent3.20
Operating Lease Liability Current0.49
Operating Lease Liability Noncurrent2.64
Total Liabilities29.72
Stockholders' Equity
Common Stock Value0.01
Additional Paid In Capital Common Stock583.67
Retained Earnings / Accumulated Deficit-495.57
Other Equity-0.61
Common Stockholder's Equity87.49
Total Stockholder's Equity87.49
Liabilities & Stockholder's Equity117.21
4 historic quarters locked

Sign in to unlock the full Y mabs Therapeutics inc balance sheet history.

About Y mabs Therapeutics Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001558370-25-010848

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.